| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $85K | — | +0.0% |
| SG&A Expense | $1.9M | — | +4.0% |
| Operating Income | -$1.9M | — | +0.5% |
| Net Income | -$1.9M | — | -16.0% |
| EPS (Basic) | -$0.30 | — | +9.1% |
| EPS (Diluted) | -$0.30 | — | +9.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $2.4M | -40.0% | -65.4% |
| Current Assets | $2.8M | -30.9% | -62.7% |
| Total Assets | $5.9M | -18.5% | -51.2% |
| Current Liabilities | $2.1M | +45.3% | -5.7% |
| Total Liabilities | $2.9M | +19.9% | -50.5% |
| Stockholders' Equity | $3.0M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$1.6M | — | +20.2% |
| Financing Cash Flow | $1.6M | — | +0.0% |
| -51.8% |